Biomarker discovery using intact, molecularly active postmortem whole human Alzheimer's disease brains

Our data show that our perfusion-based postmortem brain model can recapitulate the complexity of the brain at the cellular and systems level. This paves the way for conducting preclinical drug discovery in postmortem human disease brain, including demonstration of drug exposure at the site of action, target engagement, and functional impacts on disease-relevant endpoints, as well as optimization of brain delivery technologies. Utilizing human disease brains as a preclinical model promises to substantially increase the probability of success in developing new therapies for AD.